These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 15248218

  • 1. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG.
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [Abstract] [Full Text] [Related]

  • 3. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
    Singh G, Saxena N, Aggarwal A, Misra R.
    J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
    [Abstract] [Full Text] [Related]

  • 4. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
    Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, Fleming JA, Howell DN.
    Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 7. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical course and prognostic factors in lupus nephropathy].
    Gamba G, Quintanilla L, del Bosque MD, Chew-Wong A, Correa-Rotter R.
    Rev Invest Clin; 2000 Dec; 52(4):397-405. PubMed ID: 11061101
    [Abstract] [Full Text] [Related]

  • 10. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.
    Winoto J, Song H, Hines C, Nagaraja H, Rovin BH.
    Clin Nephrol; 2011 May; 75(5):451-7. PubMed ID: 21543025
    [Abstract] [Full Text] [Related]

  • 11. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
    Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, Flis R, Pirani C, Appel GB.
    Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC.
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [Abstract] [Full Text] [Related]

  • 15. Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience.
    Liang L, Yang X, Xu H, Zhan Z, Ye Y, Yu X, Chen W.
    J Rheumatol; 2004 Apr; 31(4):701-6. PubMed ID: 15088294
    [Abstract] [Full Text] [Related]

  • 16. Longterm followup of childhood lupus nephritis.
    Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E.
    J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
    [Abstract] [Full Text] [Related]

  • 17. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P.
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [Abstract] [Full Text] [Related]

  • 18. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
    Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB.
    Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
    [Abstract] [Full Text] [Related]

  • 19. Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis.
    Eiser AR, Grishman E, Dreznin S.
    Clin Nephrol; 1993 Sep; 40(3):155-9. PubMed ID: 8403570
    [Abstract] [Full Text] [Related]

  • 20. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC.
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.